Leal raises $45M to advance LTX-002 to clinical trials for ALS
Leal Therapeutics has raised $45 million to continue advancing its pipeline of drugs for diseases of the brain and spinal cord, including a promising new therapy for amyotrophic lateral sclerosis (ALS). The financing round, which follows an earlier $39 million investment, will help Leal move its two lead…